Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M. Lee YG, et al. Among authors: ballard hj. Cancer Discov. 2022 Oct 5;12(10):2372-2391. doi: 10.1158/2159-8290.CD-21-1026. Cancer Discov. 2022. PMID: 35904479 Free PMC article.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Svoboda J, et al. Haematologica. 2021 Jun 1;106(6):1705-1713. doi: 10.3324/haematol.2019.238675. Haematologica. 2021. PMID: 32414850 Free PMC article. Clinical Trial.
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA. Ruff A, et al. Among authors: ballard hj. Mol Imaging Biol. 2021 Dec;23(6):818-826. doi: 10.1007/s11307-021-01627-8. Epub 2021 Jul 6. Mol Imaging Biol. 2021. PMID: 34231105 Free PMC article.
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL. Nasta SD, et al. Among authors: ballard hj. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e730-e737. doi: 10.1016/j.clml.2022.04.012. Epub 2022 Apr 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35595619 Free PMC article.
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M, Schuster SJ. Ghilardi G, et al. Among authors: ballard hj. Ann Oncol. 2022 Sep;33(9):916-928. doi: 10.1016/j.annonc.2022.05.521. Epub 2022 Jun 9. Ann Oncol. 2022. PMID: 35690221 Free article.
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton R, Pajarillo R, Patel V, White G, Ballard HJ, Weber E, Napier E, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O'Connor R, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: ballard hj. Blood Adv. 2024 Feb 13;8(3):653-666. doi: 10.1182/bloodadvances.2023011492. Blood Adv. 2024. PMID: 38113468 Free PMC article.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Merryman RW, et al. Among authors: ballard hj. Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556. Blood Adv. 2021. PMID: 33710337 Free PMC article.
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Bowers JT, et al. Among authors: ballard hj. Blood Adv. 2023 Nov 14;7(21):6630-6638. doi: 10.1182/bloodadvances.2023010622. Blood Adv. 2023. PMID: 37595053 Free PMC article.
47 results